Using doxorubicin and personalized medicine to improve immunotherapy for glioblastoma.
Leveraging doxorubicin immune-modulation, blood-brain barrier opening, and personalized medicine for effective immunotherapy in glioblastoma. A mechanistic approach and pharmacokinetic trial.
This study is looking at a new way to make immunotherapy work better for people with glioblastoma by using a combination of a chemotherapy drug and a special antibody, along with ultrasound to help the treatment reach the tumor more effectively, while also figuring out which patients might benefit the most from this approach.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10910094 on NIH RePORTER |
What this research studies
This research investigates how to enhance immunotherapy for glioblastoma by using a combination of doxorubicin, a chemotherapy drug, and a novel antibody called Balstilimab. The approach involves temporarily opening the blood-brain barrier using ultrasound technology to allow better penetration of the treatment into the tumor. Additionally, the study aims to identify specific molecular markers that can predict which patients will benefit most from this therapy. By addressing the challenges of the tumor microenvironment and drug delivery, the research seeks to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have not responded to standard treatments.
Not a fit: Patients with other types of brain tumors or those who have already received extensive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with glioblastoma, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in using similar approaches to enhance drug delivery and immunotherapy effectiveness, indicating potential for success in this novel application.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Sonabend, Adam M — University of California, San Francisco
- Study coordinator: Sonabend, Adam M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.